An interventional study of Genome Sequencing in Genetic Predisposition to Disease and Hereditary Diseases, sponsored by Brigham and Women's Hospital. Active, not recruiting at 3 sites in United States. Open to participants aged 0 Months to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 with no phase, reaches primary completion later than 12 of the 45 other live ones, and was the 56th registered.
242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.
Browse Genetic Predisposition to Disease studies →37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:
University of Missouri-Columbia · Sites in United States
Ages 45–65 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Women only
Christopher Reilly · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.
This study: 0 Months to 12 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 640 is above the median of 238 across 86 interventional studies indexed under Genetic Predisposition to Disease.
Median enrollment 225 across the 37 interventional studies, 560 across the 50 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 87 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 6 studies filed under Genetic Predisposition to Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Genetic Predisposition to Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05205356Boston Children's HospitalVIGOR: Virtual Genome Center for Infant Health | 2026-12-31 |
| NCT05020574University of California, San FranciscoMicrobiome and Association With Implant Infections | 2026-12-31 |
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT06450171Dana-Farber Cancer InstituteEvaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study | 2027-01-31 |
| NCT05161169Brigham and Women's HospitalImplementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is exploring the use of genomic sequencing in the newborn period to screen healthy babies for current and future health risks. The study will enroll a diverse cohort of over 500 healthy infants and their parents from Boston, MA; New York City, NY; Birmingham, AL; and additional U.S. cities. A small blood sample will be collected from each infant, and whole genome sequencing will be performed in 1/2 of the cohort following a randomized controlled trial design. 3 months later, the randomization status and sequencing results will be shared with parents and pediatricians. Investigators will study the medical, behavioral, and economic outcomes of genomic sequencing to better understand how this technology can be implemented in outpatient primary care settings.
The objective of this research protocol is to assess the impacts of genomic sequencing in healthy infants from ethnically and racially diverse communities as part of routine pediatric care.
Investigators will enroll a cohort of over 500 healthy, ethnically and racially diverse infants from Boston, Massachusetts; New York City, New York; Birmingham, Alabama, and other U.S. cities and recruitment sites. As part of this study, a stakeholder board comprised of diverse community members will provide early and regular feedback throughout the study on anticipated and ongoing community reaction to the work with sensitivity to historical injustices and cultural diversity
Primary care pediatricians from each recruitment site will be enrolled for a brief genomics education curriculum. Only infants whose healthcare providers have joined the study will be enrolled.
A small blood sample will be obtained from each enrolled infant. Participants will randomized (1:1) to receive either a family history report or a family history report plus whole genome sequencing.
Genome sequencing data will be analyzed for pathogenic and likely pathogenic variants in genes associated with childhood-onset disease risks, as well as highly actionable adult-onset disease risks. If infants have a dominant risk identified, parents may choose to be screened as part of the study.
The study team will disclose the infant's randomization status and study results during a consultation with each family, and results will be sent to the infant's pediatrician.
Parents will be surveyed at three time points over the 12 months after enrollment: baseline, immediately post-disclosure (approximately 3 months after enrollment), and 6 months post-disclosure. Surveys will assess psychosocial impacts of newborn sequencing.
Chart reviews will be performed 12 months post-disclosure to assess the medical outcomes and healthcare utilization costs of newborn genome sequencing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infant participants
Parent participants
Exclusion Criteria:
Infants receive genome sequencing with analysis of 4,299 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.
Genetic: Genome Sequencing
Infants receive a detailed family history report plus standard well-child care.
20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
Monogenic disease risks (MDRs)
Pathogenic (P) and likely pathogenic (LP) variants identified relevant to infant's health (dominant or biallelic recessive disease risks)
Time frame: 3 months after enrollment
Carrier status variants
P and LP variants identified as recessive carrier status in infant
Time frame: 3 months after enrollment
MDR-associated phenotype
Signs or symptoms of monogenic disease risk identified by genome sequencing
Time frame: 3 months after enrollment and 1-year post-disclosure (15 months after enrollment)
Parenting stress, relationship dysfunction
Parenting Stress Index, 4th Edition Short Form (scored as a percentile 0 - 100%, higher scores indicate increased stress)
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
Relationship satisfaction
Kansas Marital Satisfaction Scale (Scored 3 to 21, higher scores indicate better marital quality)
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
General anxiety
General Anxiety Disorder-7
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
MDR-associated family history
Signs or symptoms of monogenic disease risk or recessive condition present in infant's biological family
Time frame: 3 months after enrollment and 1-year post-disclosure (15 months after enrollment)
Intervention prompted by genetic or family history report
Healthcare intervention prompted by MDR or recessive carrier variant
Time frame: 6 months post-disclosure (9 months after enrollment)
Suspected genetic condition
Any phenotype that develops in an infant or a family history suspected to have a genetic cause
Time frame: 6 months post-disclosure (9 months after enrollment)
Child vulnerability
Vulnerable Baby Scale (scored 0-50, higher scores indicate increased perceptions of child vulnerability)
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
Feelings about genomic testing
Feelings About genomiC Testing Results (FACToR) Questionnaire
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
Partner blame
Novel item (higher scores indicate increased blame)
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
General depression
Patient Health Questionnaire (PHQ)-8
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
Self blame
Novel item (higher scores indicate increased blame)
Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
Cost of attributable services
Cost of health care services associated with surveillance and diagnosis of GS and family history risks
Time frame: 6 months post-disclosure (9 months after enrollment)
Cost of genomic services
Cost of genetic services infants and parents received after study disclosure session
Time frame: 6 months post-disclosure (9 months after enrollment)
All healthcare costs
All health sector costs observed in medical records and survey questions regarding family out-of-pocket expenses
Time frame: 6 months post-disclosure (9 months after enrollment)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The study protocol and statistical analysis plan will be shared on clinical trials.gov
Supporting information: Study protocol, Statistical analysis plan
Time frame: Supporting information will be shared 6 months after study completion.
Started Dec 2022 (actual). Primary completion is estimated for Apr 2027, 52 months after the start.
Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 52 months is above that.
Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jun 2025 → Apr 2027 and completion Jun 2025 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genetic Predisposition to Disease →
Brigham and Women's Hospital →